<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among the most prominent features associated with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) are cerebral ischaemic events (CVE) </plain></SENT>
<SENT sid="1" pm="."><plain>Pregnancy with APS increases the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp>, including CVE </plain></SENT>
<SENT sid="2" pm="."><plain>This study was undertaken to assess the risk of obstetric complications and recurrence of CVE during pregnancy in women with APS and previous CVE </plain></SENT>
<SENT sid="3" pm="."><plain>We prospectively observed 23 pregnancies in 20 women (median age 31 years) with primary (n = 8) or secondary APS (n = 12) </plain></SENT>
<SENT sid="4" pm="."><plain>Eight patients had <z:e sem="disease" ids="C0007787" disease_type="Disease or Syndrome" abbrv="tia|TIA|T.I.A.">transient ischaemic attacks</z:e> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) and 12 had <z:hpo ids='HP_0001297'>stroke</z:hpo> before pregnancy </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received aspirin 100 mg daily in combination with low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) during their pregnancies </plain></SENT>
<SENT sid="6" pm="."><plain>The live birth rate was 91.3% (n = 21) </plain></SENT>
<SENT sid="7" pm="."><plain>Obstetrical complications consisted mainly of <z:e sem="disease" ids="C0032914" disease_type="Disease or Syndrome" abbrv="PEE|PREG1|PEE1">preeclampsia</z:e> (n = 8, 34.8%) and <z:hpo ids='HP_0001622'>preterm delivery</z:hpo> (n = 9, 42.9%) </plain></SENT>
<SENT sid="8" pm="."><plain>The risk for <z:e sem="disease" ids="C0032914" disease_type="Disease or Syndrome" abbrv="PEE|PREG1|PEE1">preeclampsia</z:e> increased in patients who were positive for multiple <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) (odds ratio (OR) 3.06 (95% confidence interval (CI) 1.01-9.32)) per positive aPL test (i.e anticardiolipin antibody, anti-ß2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibody, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>) (p 0.049) </plain></SENT>
<SENT sid="9" pm="."><plain>Three patients experienced recurrent CVE in the context of pregnancy (one during pregnancy, two in the postpartum period) </plain></SENT>
<SENT sid="10" pm="."><plain>We found an increased, but not significant, risk of a new episode of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in patients with pregnancies complicated by <z:e sem="disease" ids="C0032914" disease_type="Disease or Syndrome" abbrv="PEE|PREG1|PEE1">preeclampsia</z:e> (two out of the eight <z:e sem="disease" ids="C0032914" disease_type="Disease or Syndrome" abbrv="PEE|PREG1|PEE1">preeclampsia</z:e> (p 0.15) </plain></SENT>
<SENT sid="11" pm="."><plain>Despite treatment, there is a significant risk for <z:e sem="disease" ids="C0032962" disease_type="Disease or Syndrome" abbrv="">pregnancy complications</z:e> in APS patients with previous CVE </plain></SENT>
<SENT sid="12" pm="."><plain>Especially in the context of <z:e sem="disease" ids="C0032914" disease_type="Disease or Syndrome" abbrv="PEE|PREG1|PEE1">preeclampsia</z:e>, anticoagulation should be given rigorously to prevent recurrence of CVE </plain></SENT>
</text></document>